Search Results

By Christopher Hoimes, MD  / July 10, 2021

Enfortumab Vedotin Represents a Community of Work in Antibody-Drug Conjugates Targeting Cancer

The first known clinical trial report of an antibody-drug conjugate was a phase 0/I pharmacodynamic and safety study of a conjugate that targeted carcinoembryonic antigen and delivered a payload of vinca alkaloid in eight patients with ovarian or colorectal cancer.1 This work built on the work of...